Pediatric use of intravenous and intramuscular phenytoin: Lessons learned

Journal of Child Neurology

Volumn 13, Issue SUPPL. 1, 1998, Pages

  Wheless, James W ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; PHENYTOIN; PROPYLENE GLYCOL;

ANTICONVULSANT THERAPY; ARTICLE; CARDIOTOXICITY; CELLULITIS; CHILD; CHILDHOOD DISEASE; DRUG INDUCED DISEASE; EDEMA; EXTRAVASATION; HEMOLYSIS; HUMAN; INJECTION SITE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; PAIN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PURPLE GLOVE SYNDROME; SEIZURE; SYNDROME DELINEATION;

EID: 0031712201     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/0883073898013001041     Document Type: Article

References (40)

1. Schwab RS, Murphy JT: Recent experiences with parenteral Dilantin. Epilepsia 1959;1:227-231.
2. Wallis W, Kutt H, McDowell F: Intravenous diphenylhydantoin in the treatment of acute repetitive seizures. Neurology 1968;18: 513-525.
3. Murphy JT, Schwab RS: Diphenylhydantoin (Dilantin) sodium used parenterally in control of convulsions. JAMA 1956;160: 385-388.
4. Buchthal F, Svensmark O, Schiller PJ: Clinical and electroencephalographic correlations with serum levels of diphenylhydantoin. Arch Neurol 1960;2:624-630.
5. Pippenger CE, Bastiani RJ, Schneider RS: Evaluation of an experimental homogeneous enzyme immunoassay for the quantitation of phenytoin and phenobarbitone in serum or plasma, in Schneider H, Janz D, Gardner-Thorpe C, et al (eds): Clinical Pharmacology of Antiepileptic Drugs. New York, Springer-Verlag, 1975, pp 331-336.
6. Physicians' Desk Reference, 16th ed. Oradell, NJ, Medical Economics Co, 1962, p 748.
7. Physicians' Desk Reference, 40th ed. Oradell, NJ, Medical Economics Co, 1986, p 1337.
8. Loughnan PM, Greenwald A, Purton WW, et al: Pharmacokinetic observations of phenytoin disposition in the newborn and young infant. Arch Dis Child 1977;52:302-309.
9. Painter MJ, Pippinger C, MacDonald H, Pitlick W: Phenobarbital and diphenylhydantoin levels in neonates with seizures. J Pediatr 1978;92:315-319.
10. Carter CH: Use of parenteral diphenylhydantoin (Dilantin) sodium in control of status epilepticus. Arch Neurol Psychiatr 1958;79: 136-137.
11. McWilliam PKA, Leeds MB: Intravenous phenytoin sodium in continuous convulsions in children. Lancet 1958;2:1147-1149.
12. Koren G, Brand N, Halkin H, et al: Kinetics of intravenous phenytoin in children. Pediatr Pharmacol 1984;4:31-38.
13. Wilder BJ, Ramsay RE, Willmore LJ, et al: Efficacy of intravenous phenytoin in the treatment of status epilepticus: Kinetics of central nervous system penetration. Ann Neurol 1977;1:511-518.
14. Koren G, Barzilay Z, Schachar E, et al: Kinetics of CSF phenytoin in children. Can J Neurol Sci 1983;10:195-197.
15. Jaimovich DG, Shabino CL, Ringer TV, Peters GR: Comparison of intraosseous and intravenous routes of anticonvulsant administration in a porcine model. Ann Emerg Med 1989;18:842-846.
16. Vinsel PJ, Moore GP, O'Hair KC: Comparison of intraosseous versus intravenous loading of phenytoin in pigs and effect on bone marrow. Am J Emerg Med 1990;8:181-183.
17. Dam M, Olesen V: Intramuscular administration of phenytoin. Neurology 1966;16:288-292.
18. Kostenbauder HB, Rapp RP, McGovren JP, et al: Bioavailability and single-dose pharmacokinetics of intramuscular phenytoin. Clin Pharmacol Ther 1975;18:449-456.
19. Serrano EE, Wilder BJ: Intramuscular administration of diphenylhydantoin. Arch Neurol 1974;31:276-278.
20. Tuttle CB: Intramuscular injections and bioavailability. Am J Hosp Pharm 1977;34:965-968.
21. Rao VK, Feldman PD, Dibbell DG: Extravasation injury to the hand by intravenous phenytoin. J Neurosurg 1988;68:967-969.
22. Hagan HJ, Hasting H: Extravasation of phenytoin in the hand. J Hand Surg 1988;13A:942-943.
23. Grinder D, Guastella CP, Pellegrino M: Soft-tissue damage and intravenous phenytoin. Drug Intel Clin Pharmacol 1988;22:725-726.
24. Hunt SJ: Cutaneous necrosis and multinucleate epidermal cells associated with intravenous phenytoin. Am J Dermatopathol 1995;17:399-402.
25. Comer JB: More on phenytoin injection precautions, letter. Clin Pharmacol 1986;5:717.
26. Williams KG: More on phenytoin injection precautions, letter. Clin Pharmacol 1986;5:717.
27. Reeme PD, Day DL: Phenytoin injection precautions. Clin Pharmacol 1985;4:618-620.
28. Comer JB: Extravasation from intravenous phenytoin. Am J Intravenous Ther Clin Nutr 1984;11:23-29.
29. Kilarski DJ, Buchanan C, Von Behren L: Soft-tissue damage associated with intravenous phenytoin. N Engl J Med 1984;311: 1186-1187.
30. Hanna DR: Purple glove syndrome: A complication of intravenous phenytoin. J Neurosci Nurs 1992;24:340-345.
31. Helfaer MA, Ware C: Purple glove syndrome. J Neurosurg Anesthesiol 1994;6:48-49.
32. O'Brien TJ, Cascino GD, So EL, Hanna DR: Incidence and clinical consequences of the purple-glove syndrome in patients receiving intravenous phenytoin, abstract. Epilepsia 1997;38(Suppl 8): 90-91.
33. Arulanantham K, Genel M: Central nervous system toxicity associated with ingestion of propylene glycol. J Pediatr 1978;93: 515-516.
34. Demey HE, Daelemans RA, Verpooten GA, et al: Propylene glycol-induced side effects during intravenous nitroglycerin therapy. Intensive Care Med 1988;14:221-226.
35. MacDonald MG, Getson PR, Glasgow AM, et al: Propylene glycol: Increased incidence of seizures in low birth weight infants. Pediatrics 1987;79:622-625.
36. Glover ML, Reed MD: Propylene glycol: The safe diluent that continues to do harm. Pharmacotherapy 1996;16:690-693.
37. Joint Food and Agriculture Organization/WHO Expert Committee on Food Additives: Toxicological Evaluation of Some Food Additives. Technical Report Series No. 539. Geneva, World Health Organization, 1974, pp 270-277.
38. Earnest MP, Marx JA, Drury LR: Complications of intravenous phenytoin for acute treatment of seizures: Recommendations for usage. JAMA 1983;249:762-765.
39. Spengler RF, Arrowsmith JB, Kilarski DJ, et al: Severe soft-tissue injury following intravenous infusion of phenytoin. Arch Intern Med 1988;148:1329-1333.
40. Jamerson BD, Dukes GE, Brouwer KLR, et al: Venous irritation related to intravenous administration of phenytoin versus fosphenytoin. Pharmacotherapy 1994;14:47-52.